A carregar...
Ixekizumab for the Treatment of Psoriasis: A Review of Phase III Trials
INTRODUCTION: Interleukin-17 inhibitors are the newest class of monoclonal antibodies approved by the US Food and Drug Administration for the treatment of psoriasis. Preclinical and Phase II studies of ixekizumab, a high-affinity anti-IL-17A monoclonal antibody, have proved promising. METHODS: We co...
Na minha lista:
| Publicado no: | Dermatol Ther (Heidelb) |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer Healthcare
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4799032/ https://ncbi.nlm.nih.gov/pubmed/26910853 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13555-016-0102-0 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|